A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
for Solid Tumor Malignancies
Sites in Charleston +5 more locations
Sponsor: A2A Pharmaceuticals Inc.
Sex: All·Age: 18+
Code: NCT06136884·Phase 1·Recruiting·Listed Nov 2023